HEALTH & MEDICINE

   GPC Biotech AG announced the appointment of Torsten Hombeck to chief financial officer. Mr. Hombeck will assume his duties on January 1. He will replace Mirko Scherer who is resigning from the company to pursue other interests. Mr. Scherer will remain a consultant to GPC Biotech.
   Mr. Hombeck joined GPC in 1999 and has worked out of the company’s U.S. offices as vice president, finance since 2002. He will continue to be based in Plainsboro.
   Prior to joining GPC Biotech, he held positions in corporate finance and controlling, including financial oversight responsibility for South America, at Beiersdorf AG, an international consumer products company.
   GPC Biotech is headquartered in Martinsried/Munich, Germany, and has a wholly owned U.S. subsidiary headquartered in Plainsboro.

* * *

   Celator Pharmaceuticals announced two recent appointments to its scientific advisory board:
   Dr. Frederick R. Appelbaum, head of the University of Washington School of Medicine’s Division of Medical Oncology and president of the Seattle Cancer Care Alliance. Prior to joining the faculty of the University of Washington in 1978, Dr. Appelbaum was a clinical associate and investigator with the National Cancer Institute in Bethesda, Md.
   Dr. Ross C. Donehower, professor of oncology and medicine at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. He is also director of the division of medical oncology at the Johns Hopkins Oncology Center. His clinical research has focused on the treatment of gastrointestinal and lung cancers as well as new drug development. Before joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate with the National Cancer Institute.
   Celator Pharmaceuticals Inc., based in Plainsboro, is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer.